<DOC>
	<DOCNO>NCT01912534</DOCNO>
	<brief_summary>The purpose trial determine whether treatment valsartan beneficial effect early hypertrophic cardiomyopathy ( HCM ) assess many domain reflect myocardial structure , function biochemistry .</brief_summary>
	<brief_title>Valsartan Attenuating Disease Evolution In Early Sarcomeric HCM</brief_title>
	<detailed_description>This multicenter , double-blind , placebo-controlled Phase II , randomize clinical trial ass safety efficacy valsartan attenuate disease evolution early HCM . Sarcomere mutation carrier asymptomatic mildly symptomatic overt disease ( NYHA class I-II ) , mutation carrier without left ventricular hypertrophy ( LVH ) study .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . All subject must Pathogenic Likely Pathogenic HCM Sarcomere Mutation . The following category mutation consider acceptable subject previously undergone clinical genetic testing . If result ambiguous , review Clinical Coordinating Center determine eligibility . Laboratory Molecular Medicine ( Pathogenic , Likely Pathogenic ) Transgenomics/ PGXHealth ( Class I ) GeneDx ( Disease causing ; Variant ; likely diseasecausing ; Published , diseasecausing mutation ; Novel , likely diseasecausing , mutation ) Correlagen ( Associated ; Probably Associated ) Group 1 ( Overt HCM Cohort ) 1 . LV wall thickness ≥12 mm ≤25 mm z score ≥3 ≤18 determine rapid assessment echocardiographic core laboratory 2 . NYHA functional class I II ; perceive slight limitation physical activity 3 . No rest provokable LV obstruction ( peak gradient ≤ 30 mmHg ) clinicallyobtained Exercise Tolerance Test ( ETT ) echo within past 24 month transthoracic echo Valsalva maneuver within past 12 month 4 . Age 845 year 5 . Able attend followup appointment , complete study assessment , provide write informed consent Group 2 ( Preclinical HCM Cohort ( G+/LVH ) ) 1 . LV Wall Thickness &lt; 12 mm z score &lt; 3 , determine rapid assessment echocardiographic core laboratory 2 . Age 1025 year 3 . E ' z score ≤ 1.5 OR ECG abnormalities NSSTW change ( Q wave , T wave inversion , repolarization change ) OR LV wall thickness zscore 1.52.9 combined LV thickness dimension ratio ≥0.19 ( determine rapid assessment echocardiographic core laboratory ) 4 . Able attend followup appointment , complete study assessment , provide write informed consent Subject Exclusion Criteria 1 . Contraindication angiotensin receptor blocker ( ARB ) administration , include impaired renal function , hyperkalemia ( serum K &gt; 5.0 mmol/L ) , prior history angioedema 2 . Medical condition associate increased collagen turnover may confound interpretation biomarkers collagen synthesis ( liver , pulmonary renal fibrosis , inflammatory state , cancer , trauma surgery within 6 month enrollment ) 3 . Concomitant use Spironolactone , Lithium , Aliskiren , ARB ACEinhibitors . If drug active use necessary medical care , may discontinue baseline study perform 2week washout period . 4 . Pregnant breastfeeding female Females childbearing potential effective contraceptive method ( include abstinence ) 5 . Uncontrolled systemic HTN [ persistent SBP &gt; 160 and/or DBP &gt; 90 adult equivalent child ( e.g. , SBP &gt; 99th DBP &gt; 95th percentile sex , age , height centile base American Academy Pediatrics normal value ) ] 6 . Obstructive physiology , define resting , Valsalvaprovoked exerciseinduced gradient &gt; 30mmHg within past 24 month 7 . Prior septal myectomy alcohol septal ablation 8 . Known , suspect , symptomatic coronary artery disease evidence prior myocardial infarction base symptom cardiac image 9 . More mild valvular heart disease clinically significant congenital heart disease . Allowable condition include bicuspid aortic valve without clinically significant stenosis regurgitation ; spontaneously close ventricular septal defect ; patent foramen ovale , small ( ≤ 2 mm ) restrictive ventricular septal defect normal ventricular size , minor defect consider allowable [ review consensus participate pediatric cardiologist , overall study PI ] adjudication echocardiographic core laboratory . 10 . Left ventricular ejection fraction ( LVEF ) &lt; 55 % 11 . Concomitant medical condition would preclude performance confound interpretation echocardiography , exercise testing , CMR ( e.g. , renal insufficiency , lung disease , orthopedic/rheumatologic condition , atrial fibrillation ) 12 . Secondary prevention implantable cardioverterdefibrillator device ( ICD ; primary prevention ICDs without history appropriate therapy , include shock ATP , allowable ) . 13 . Prior treatment hospitalization symptomatic heart failure 14 . Participation clinical trial ( except observational study ) involve investigational medication within previous 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sarcomere Mutations</keyword>
</DOC>